Publicaciones en colaboración con investigadores/as de University of Groningen (17)

2024

  1. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2020

  1. NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  2. Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

2016

  1. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 6, pp. 965-973

2015

  1. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility

    American Journal of Human Genetics, Vol. 96, Núm. 4, pp. 565-580

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  3. Inter-laboratory evaluation of instrument platforms and experimental workflows for quantitative accuracy and reproducibility assessment

    EuPA Open Proteomics, Vol. 8, pp. 6-15

2014

  1. Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus

    Arthritis Research and Therapy, Vol. 16, Núm. 3

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2012

  1. Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study

    PLoS ONE, Vol. 7, Núm. 9

  2. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: A randomised, placebo controlled, proof-of-concept study

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 2, pp. 180-185

2011

  1. Association of systemic lupus erythematosus clinical features with european population genetic substructure

    PLoS ONE, Vol. 6, Núm. 12

2010

  1. Series "update on tuberculosis" edited by C. Lange, M. Raviglione, W.W. Yew and G.B. Migliori number 2 in this series: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement

    European Respiratory Journal, Vol. 36, Núm. 5, pp. 1185-1206

2009

  1. Replication of recently identified systemic lupus erythematosus genetic associations: A case-control study

    Arthritis Research and Therapy, Vol. 11, Núm. 3

2007

  1. Opposed independent effects and epistasis in the complex association of IRF5 to SLE

    Genes and Immunity, Vol. 8, Núm. 5, pp. 429-438